OPK

OPK

USD

OPKO Health Inc. Common Stock

$1.410+0.040 (2.920%)

Цена в режиме реального времени

Healthcare
Diagnostics & Research
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$1.370

Максимум

$1.430

Минимум

$1.370

Объем

2.69M

Фундаментальные показатели компании

Рыночная капитализация

1.1B

Отрасль

Diagnostics & Research

Страна

United States

Статистические данные торговли

Средний объем

2.21M

Биржа

NMS

Валюта

USD

52-недельный диапазон

Минимум $1.11Текущая $1.410Максимум $2.04

Связанные новости

Analyst Upgrades

Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6

Jefferies analyst Maury Raycroft downgrades OPKO Health from Buy to Hold and lowers the price target from $2 to $1.6.

Просмотреть больше
Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6
Analyst Upgrades

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

Barrington Research analyst Michael Petusky maintains OPKO Health with a Outperform and maintains $2.25 price target.

Просмотреть больше
Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target
GlobeNewswire

OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) --

Просмотреть больше
OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
GlobeNewswire

OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28,

Просмотреть больше
OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
GlobeNewswire

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial

Просмотреть больше
OPKO Health to Report Third Quarter 2025 Financial Results on October 29

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.